Acute cystitis is one of the commonest medical problems encountered by primary care physicians. It affects more women than men (8:1), but the incidence among men is increasing. Uncomplicated cystitis by definition occurs in healthy patients with a normal urinary tract, whereas complicated cystitis implies a predisposing or underlying condition. A narrow range of aetiological agents is responsible for most uncomplicated cystitis in women (Escherichia coli in 80% of cases). Recently, however, pathogens usually associated with sexually transmitted disease have been implicated. In women with typical symptoms of acute uncomplicated cystitis, an abbreviated laboratory work-up followed by empirical therapy is recommended. Single-dose and 3 day regimens of co-trimoxazole and the quinolones are as effective as longer regimens and have a higher eradication rate than other commonly used antimicrobials. Relapse rates are slightly higher with single-dose therapy. With this success rate plus the reduced cost and improved patient compliance, these regimens have replaced traditional 5 to 14 day courses of treatment. With increasing resistance of the common urinary pathogens to amoxycillin and, now, co-trimoxazole, the quinolones are a logical choice for empirical therapy of uncomplicated urinary tract infections.
Introduction
Urinary tract infection (UTI) is a frequent medical problem, accounting for more than seven million office visits to physicians in the USA annually. 1, 2 Over one million inpatient stays are related to UTI, either as the cause of or as a complication of hospitalization. 1 The four major risk groups for community-acquired UTI are school-aged girls, young women in their sexually active years, males with prostatic obstruction, and the elderly. 3 However, acute infections most frequently affect women. After the first 3 months of life, the incidence in females is eight times that in males. Approximately 40% of women report UTI during their lifetime. 4 
Aetiology and pathogenesis
A shorter urethra and lack of prostatic secretions are probably responsible for the increased incidence of UTI in females. Escherichia coli strains that typically cause infection originate in faecal flora, subsequently colonizing the vaginal introitus and urethra before infecting the bladder. 3 Host factors such as the frequency of sexual intercourse, urinary voiding patterns, genetic predisposition and the patient's immunocompetency may affect the susceptibility to recurrent infection. In some women, an increased likelihood of colonization may be associated with an increase in the susceptibility of vaginal and uroepithelial cells to adherent E. coli. 3 Behavioural factors in women are also thought to be important. Sexual intercourse facilitates migration of microorganisms from the periurethral area into the urethra and bladder. Also, use of spermicides can modify thevaginal environment and, therefore, the bacterial flora, leading to a vaginal 'reservoir' of uropathogens.
UTIs in older boys and male adolescents are rare. Most cases result from an underlying structural abnormality or instrumentation of the urinary tract. Recently, the prevalence of UTI in young men has increased. Postulated risk factors in younger men include lack of circumcision, having a sexual partner with vaginal colonization by uropathogens, and homosexuality, 5 which can result in exposure to E. coli through anal intercourse. By the age of 65, the incidence of UTI in men approaches that in women. UTIs in older men are often associated with underlying infections of the prostate.
Cystitis, defined as infection localized to the bladder, is categorized as either 'uncomplicated' or 'complicated' based on the absence or presence, respectively, of conditions that predispose to infection or contribute to the persistence of infection. Uncomplicated cystitis is an infection in a patient with an anatomically normal urinary tract who has no metabolic or functional disorders. In contrast, complicated cystitis implies the presence of a structural abnormality or a predisposing lesion such as a stone, a stricture or, in men, prostate disease. Cystitis is also considered complicated if it occurs during pregnancy or in patients with immunosuppression or significant underlying disease, such as diabetes mellitus.
Cystitis in patients presenting with a clinical picture of acute pyelonephritis (temperature Ͼ38.3°C, flank pain and tenderness of the costovertebral angle) should also be classified as complicated. Factors that suggest complicated cystitis include a history of three or more infections in the past year, a history of childhood infections, and recent antibiotic use. Patients with complicated UTI may be infected with more than one pathogen and these may be resistant to one or more antibiotics.
Approximately 20% of young women with an initial episode of cystitis have subsequent infections. 1, 6 Well over 90% of these represent reinfection by a different organism rather than relapse (recurrence due to the original microorganism). 4 Typically, these reinfections occur months apart, and can be associated with the use of diaphragms and spermicides. Recurrent cystitis can be defined as at least four separate episodes of UTI. 7 Factors favouring recurrent cystitis include malformation of the urinary tract, urolithiasis, bladder reflux and modification of the urethral meatus. Frequency and type of sexual relations, excessive vaginal douching and constricting undergarments may also play a role. 
Pathogens associated with acute cystitis
Eighty percent or so of infections in young women with acute uncomplicated cystitis are caused by E. coli, and 5-15% by Staphylococcus saprophyticus.
1 Klebsiella spp. and Proteus mirabilis are also associated with this condition. A broader range of bacteria can cause complicated infections, although E. coli again predominates. An increase in the incidence of antibiotic-resistant strains of these common pathogens has complicated the empirical approach to antibiotic management of UTI. The general decrease in susceptibility of urinary pathogens to common antibiotics is being observed worldwide; in one survey of urinary pathogens isolated from South African patients with community-acquired infections, the majority of isolates were found to be resistant to amoxycillin and cotrimoxazole, with the proportion of resistant E. coli isolates increasing during the 5 year study period. 8 Similar changes in the susceptibilities of urinary pathogens have been reported in the UK. 9 However, analyses conducted in South Africa and the UK have found that communityacquired urinary pathogens have remained highly susceptible to aminoglycosides, fluoroquinolones and some second-generation cephalosporins. Similarly, high susceptibility to fluoroquinolones has been observed in multidrug-resistant urinary pathogens identified in the USA. 10 In recent decades, our understanding of the aetiology of UTI has undergone some change. 2 Pathogens usually associated with sexually transmitted disease are now being implicated. Both men and women may present with UTI caused by Neisseria gonorrhoeae, Trichomonas vaginalis, Chlamydia trachomatis or Ureaplasma urealyticum. Herpes simplex virus may also infect the urinary tract and cause dysuria. 
Diagnosis
Typically, acute cystitis in a young woman presents with dysuria. Other conditions causing dysuria include acute urethritis and vaginitis. Absence of discharge helps to exclude vaginitis, but urethritis can be more difficult to distinguish, although it typically lacks the suprapubic tenderness found in acute cystitis. Urinalysis can assist in differentiating these conditions (Table I) . Careful history taking is mandatory to screen for the complicating factors described above.
Since the causative organisms and their antimicrobial susceptibility profiles are so predictable in women with acute cystitis, an abbreviated laboratory workup followed by empirical therapy is recommended. 1 In patients with typical symptoms, diagnosis is presumed if pyuria is present on microscopy or by leucocyte esterase testing. On urinalysis, the pH of the urine may be alkaline because of the byproducts created by the metabolism of urea-splitting pathogens such as Proteus spp. Proteinurea is usually minimal (Ͻ0.6 g/m 2 /day) and the urine protein:creatinine ratio is Ͻ0.6. In patients with typical symptoms a urine culture may not be necessary. In addition, a follow-up visit or culture may not be needed after treatment unless symptoms persist or recur. Even with appropriate therapy for uncomplicated cystitis it may take 24 h for dysuria to resolve. If pyuria is absent or if atypical clinical features or factors suggest a complicated infection, a urine culture should be performed before initiation of therapy. Empirical antibiotic therapy may then be started, especially if there is significant discomfort. Also, a specific antibiotic can be selected later based on culture and susceptibility results. A urine culture demonstrating у10 4 cfu/mL of a pathogenic species usually indicates infection in symptomatic young women.
1 Antibiotic susceptibility testing can guide drug selection, and is also useful for epidemiological reasons.
Therapy
A suitable antimicrobial agent for the treatment of acute uncomplicated cystitis should be selected on the basis of several factors. These include the age of the patient, the presence of complicating host factors, the likely aetiological agent, community antibiotic susceptibility patterns (particularly for E. coli), the likelihood of patient compliance for a given regimen based on frequency of dosing, and, of course, cost. Pharmacokinetic parameters such as the rate of renal excretion and the length of time for which therapeutic urinary concentrations are maintained should also be considered.
Many antibiotic agents are available for the empirical treatment of acute uncomplicated cystitis, including traditional agents like co-trimoxazole, amoxycillin and the cephalosporins (particularly the second-generation compounds cefuroxime and cefaclor, but oral third-generation cephalosporins such as cefixime and cefpodoxime have also been used), and newer agents such as the fluoroquinolones.
Co-trimoxazole has relatively broad-spectrum activity against common urinary pathogens. As discussed below, recent experience with short-term regimens suggests that 3 day regimens may be as effective and better tolerated than traditional 10-14 day regimens of co-trimoxazole for the treatment of acute uncomplicated cystitis. Similarly, short-term regimens employing amoxycillin and selected cephalosporins are effective against common pathogens, although their activity may be limited by the emergence of resistant strains.
With the progressive development of resistance among community-acquired pathogens and potential side effects of standard treatment regimens, the fluoroquinolones have been identified as useful alternatives for the management of acute uncomplicated cystitis. Currently, for example, half of the strains causing uncomplicated cystitis in the USA demonstrate in-vitro resistance to amoxycillin and sulphonamides. Furthermore, overall resistance to trimethoprim and co-trimoxazole is 5-15% and appears to be increasing. 1 Based on their analysis of susceptibility of community-acquired urinary pathogens in South Africa, Maartens & Oliver 8 have recommended that co-trimoxazole should not be prescribed empirically for UTI unless a susceptible isolate has been cultured. There is some geographical variability in antibiotic resistance. Resistance to the fluoroquinolones remains below 5% nationwide.
The fluoroquinolones have a wide spectrum of activity against Gram-positive and Gram-negative bacteria, unique pharmacokinetics and good patient acceptance. Enoxacin, norfloxacin, ciprofloxacin, lomefloxacin, ofloxacin and levofloxacin are among the commercially available fluorinated derivatives of the prototype quinolone. They are rapidly absorbed after oral administration and reach peak serum concentrations in 1-2 h.
2,11 Selected fluoroquinolones are effective against resistant strains of Pseudomonas aeruginosa and Acinetobacter spp. Strains of N. gonorrhoeae are almost all susceptible to all quinolones. Staphylococcus aureus, coagulase-negative staphylococci and enterococci are generally inhibited by urinary concentrations of these drugs that can be attained with usual dosing regimens.
In most studies, the rates of eradication of uropathogens approach 100% after use of fluoroquinolones (Table II) . For example, ciprofloxacin demonstrated cure rates of 87-100% among women with uncomplicated cystitis who were treated for 10 days. 2 Similarly, an analysis of 734 UTIs treated with oral ciprofloxacin found an 88.8% cure rate and a bacteriological response rate of 94% among the 780 organisms isolated. 12 Comparable response rates have been observed in women treated with norfloxacin.
Another fluoroquinolone, ofloxacin, has also been used for the treatment of uncomplicated UTI. Ludwig 13 found that ofloxacin had a higher response rate than nitrofurantoin in treating lower UTI; however, these results may have favoured ofloxacin because the proportion of patients who discontinued the study because of adverse events was greater among the patients taking nitrofurantoin. Fluoroquinolones, such as ofloxacin and norfloxacin, have also demonstrated effectiveness against Klebsiella pneumoniae, Klebsiella oxytoca and Enterobacter agglomerans.
14 The susceptibility of P. aeruginosa varies among fluoroquinolones; furthermore, the susceptibility of this pathogen to these agents is often greater when it is isolated from patients with uncomplicated UTI than from those with complicated UTI. 15 A review 15 of randomized comparative trials of quinolones concluded that norfloxacin, ciprofloxacin and ofloxacin are at least as effective as co-trimoxazole and amoxycillin, and are usually superior to nalidixic acid, pipemidic acid and nitrofurantoin for the treatment of uncomplicated UTI (Table III) .
Duration of therapy
One of the most perplexing questions in treating UTI is the appropriate duration of treatment. Traditional treatment regimens have involved 5-7 days of therapy. However, therapy of this duration can be limited by poor patient compliance, development of adverse effects and the emergence of resistance. As a consequence, an alternative to longcourse therapy has been sought for the empirical treatment of acute cystitis. Single doses of antibiotics have been evaluated as a treatment for female patients with acute, uncomplicated UTI. Advantages of single-dose therapy include fewer adverse effects, good patient compliance, lower potential for the emergence of antibiotic resistance and lower cost. For example, cefuroxime axetil has demonstrated a bacteriological and clinical cure rate of 88% in women 1 week after a single oral dose.
2 Because a single 500 or 750 mg oral dose of ciprofloxacin results in urine concentrations that are above the MIC for most urinary pathogens, considerable attention has been given to the effectiveness of singledose quinolone therapy. 16 Treatment of patients with uncomplicated lower UTI with a single 500 mg oral dose of ciprofloxacin resulted in a bacteriological eradication rate a The minimum number of strains required to be reported in this Table was five. The total number of strains isolated before treatment was calculated by summarizing the data from all trials of the fluoroquinolones for the treatment of uncomplicated or complicated UTI. Eradication rates (%) were the number of isolates of one bacterial species eradicated at follow-up divided by the total number of isolates of the same species found before treatment.
of 89% and a clinical success rate of 94%. 17 In one study of uncomplicated UTI in women, a single 100 mg dose of ofloxacin resulted in a 94% clinical and microbiological cure rate. 18 However, single-dose regimens with co-trimoxazole are less effective than a 10 day course in eradicating E. coli from vaginal flora. 19 This vaginal colonization can lead to frequent, early relapse.
Single-dose therapy may result in lower rates of cure. Arav-Boger et al. 20 compared a single dose of 1200 mg norfloxacin with a 7 day course of norfloxacin 400 mg bd; they found cure rates of 84% with the single dose and 98% with the 7 day regimen. There is also concern about more frequent recurrence with single-dose regimens and singledose treatment with a fluoroquinolone may be prone to Total number of patients in study.
failure in patients infected with some resistant strains of S. saprophyticus. 21 Consequently, it has been suggested that an intermediate duration of treatment, 3 days, may provide an optimal balance between antibacterial effect and patient compliance. 19 Various 3 day oral antibiotic regimens have been shown to be effective, including co-trimoxazole (960 mg bd), trimethoprim (100 mg bd), norfloxacin (400 mg bd), ciprofloxacin (100 mg bd), ofloxacin (200 mg bd), lomefloxacin (400 mg once daily), enoxacin (400 mg bd), macrocrystalline nitrofurantoin (100 mg qds), amoxycillin (250 mg tds) and cefpodoxime proxetil (100 mg bd).
A number of large, double-blind studies have evaluated the effectiveness of ciprofloxacin 100 mg bd for 3 days for the treatment of acute uncomplicated lower UTI in women. In one study, 713 women were randomized to treatment with ciprofloxacin 100 mg bd for 3 days, or cotrimoxazole bd for 7 days or nitrofurantoin 100 mg bd for 7 days. 22 The most commonly isolated pathogen was E. coli (83%). At the end of therapy, the bacteriological response (eradication) was 88% in the ciprofloxacin group, 93% in the co-trimoxazole group, and 86% in the nitrofurantoin group; the eradication rate for ciprofloxacin was not statistically different from that of the comparator agents. The clinical response was also comparable among groups (ciprofloxacin, 95%; co-trimoxazole, 95%; nitrofurantoin, 93%). However, at the 4 week follow-up, the incidence of recurrence was significantly (P Ͻ 0.05) lower in the ciprofloxacin group (9%) than in the co-trimoxazole group (22%) and the nitrofurantoin group (18%). All treatments were comparably well tolerated. In another study, 866 women were randomized to treatment with either ciprofloxacin 100 mg bd for 3 days, co-trimoxazole bd for 7 days or ofloxacin 200 mg bd for 3 days. 23 Again, the most commonly isolated pathogen was E. coli (81%). Bacteriological response (eradication) at the end of therapy was 94% in the ciprofloxacin group, 93% in the co-trimoxazole group and 97% in the ofloxacin group; the difference between ciprofloxacin and the comparator agents was not statistically significant. Clinical response was also comparable among groups (ciprofloxacin, 93%; co-trimoxazole, 95%; ofloxacin, 96%). At the 4 week follow-up, the incidence of recurrence was again lower in the ciprofloxacin group (5%) than in the co-trimoxazole group (12%) and the ofloxacin group (9%). Ciprofloxacin treatment also caused significantly fewer adverse events than co-trimoxazole (P ϭ 0.034); there were significantly fewer adverse events in the nervous system with ciprofloxacin than with either of the two comparator agents.
An analysis of 679 women with acute uncomplicated UTI who were treated with ciprofloxacin 100 mg bd for 3 days in three multicentre, double-blind trials found a 92% eradication rate at the end of therapy, with persistence in 7% of women and superinfection in 1% of the cases. 17 At the end of a 4-6 week follow-up period, eradication was maintained in 91% of women. The clinical response at the end of therapy (resolved/improved) was 95%, with 5% being considered therapy failures. The comparator regimens assessed in these trials were ciprofloxacin 250 mg bd for 3 or 7 days, co-trimoxazole bd for 3 or 7 days, nitrofurantoin 100 mg bd for 7 days or ofloxacin 200 mg bd for 3 days. The findings of this analysis indicated that low-dose, 3 day therapy with ciprofloxacin 100 mg bd for 3 days was either equivalent or superior to these regimens for bacteriological response. Ciprofloxacin was also better tolerated than ofloxacin, nitrofurantoin and co-trimoxazole, particularly with respect to nervous system events and rash. Furthermore, those treated with ciprofloxacin completed their treatment more frequently than patients treated with co-trimoxazole or nitrofurantoin.
Iravani 24 compared 3 days of once-daily temafloxacin treatment with 7 days of ciprofloxacin, temafloxacin or cotrimoxazole. He found that the 3 day regimen gave a 99% rate of cure, statistically no different from the 100% rate of cure found with the 7 day courses. Iravani et al. 17 subsequently evaluated 1, 3, 5 and 7 day courses of ciprofloxacin, along with 7 day treatment with norfloxacin. Both 3 and 5 days of treatment were as effective as 7 days, all having 97-100% clinical response. Single-dose therapy was not statistically as effective, although it resulted in a 94% clinical response. Similarly, the bacteriological eradication rate was as high with 3 day regimens of ciprofloxacin as with 5 or 7 day regimens of ciprofloxacin or a 7 day regimen of norfloxacin (Table IV) . Stein & Philip 25 compared 3 days of temafloxacin, 400 mg daily, with 7 days of ciprofloxacin 250 mg bd and found no difference in the bacteriological or clinical rate of cure. A randomized comparative trial by Hooton et al. 26 found that a 3 day regimen using cotrimoxazole was more effective than were 3 day treatments with nitrofurantoin macrocrystals, cefadroxil or amoxycillin. According to Williams, 4 a 3 day course of co-trimoxazole is the treatment of choice for most uncomplicated infections, not only because it is often as effective as longer courses of therapy, but also because it is readily accepted by patients, who find compliance with a 3 day regimen to be easy.
Results of a meta-analysis by Stamm & Hooton 1 indicate that 3 day therapy with co-trimoxazole or fluoroquinolones is more effective than use of a single dose. This analysis also concluded that regimens of у7 days offered no additional therapeutic benefit despite greater cost and substantially more adverse effects. Therefore, 7 day regimens can be reserved for patients with complicating factors such as pregnancy, when there are lower rates of cure with shorter regimens. In most cases of uncomplicated acute cystitis, 3 day regimens appear optimal and have an efficacy comparable to that of 7 day regimens but with fewer adverse effects (Table IV) . 1, 27, 28 The cost of various antimicrobial regimens must, of course, also be considered. A recent cost analysis 26 of 3 day antimicrobial regimens for the treatment of uncomplicated cystitis in women concluded that co-trimoxazole was less expensive than 3 day regimens of nitrofurantoin, cefadroxil or amoxycillin. However, this study did not perform a cost analysis of other commonly used antimicrobial agents. At the same time, the relatively low incidence of adverse effects associated with the newer fluoroquinolones compared with co-trimoxazole or amoxycillin may have pharmacoeconomic value beyond drug acquisition cost alone.
Conclusion
Acute uncomplicated cystitis is one of the most common community-acquired infections. When appropriately defined, acute uncomplicated cystitis is suitable for shortterm empirical antibiotic treatment. The clinician can now select from a variety of agents that possess a broad spectrum of activity with well-tolerated safety profiles and convenient dosage regimens. The newer short-term therapies, especially 3 day regimens, are highly effective and have the benefits of improved patient compliance, and potentially decreased emergence of resistance. Single-dose therapies have somewhat lower efficacy than 3 day or traditional therapies and a higher relapse rate. They should be reserved for those who have uncomplicated UTIs and who are at lower risk for occult upper tract infections.
